These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 6627754)

  • 1. Pharmacokinetics of an osmotically controlled delivery indomethacin preparation in normal volunteers.
    Bertouch JV; Maycock S; Harrington B; Brooks PM
    Clin Exp Pharmacol Physiol; 1983; 10(4):411-4. PubMed ID: 6627754
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative multiple dose kinetics of two formulations of indomethacin.
    Verbesselt R; Tjandramaga TB; Mullie A; De Schepper PJ; Cook T; Derouwaux C; Kramp R; Hwang S
    Eur J Clin Pharmacol; 1983; 24(4):563-8. PubMed ID: 6861873
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Indomethacin kinetics and urinary excretion of prostaglandin E2 following oral administration of various dosage forms of indomethacin].
    Düsing R; Dittrich P; Kukovetz WR; Lehmann K; Kramer HJ
    Z Rheumatol; 1983; 42(4):235-41. PubMed ID: 6580789
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Kinetics of osmotically controlled indomethacin delivery systems after repeated dosing.
    Bayne W; Place V; Theeuwes F; Rogers JD; Lee RB; Davies RO; Kwan KC
    Clin Pharmacol Ther; 1982 Aug; 32(2):270-6. PubMed ID: 7094513
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Indomethacin sustained-release?
    Green JA
    Drug Intell Clin Pharm; 1984 Dec; 18(12):1004-7. PubMed ID: 6391883
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of a sustained-release product of indomethacin in the elderly.
    Bruguerolle B; Barbeau G; Bélanger PM; Labrecque G
    Gerontology; 1986; 32(5):277-85. PubMed ID: 3569930
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biopharmaceutical evaluation of 'Osmosin'.
    Rogers JD
    Curr Med Res Opin; 1983; 8 Suppl 2():38-54. PubMed ID: 6851625
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bioavailability of indomethacin from two multiple-units controlled-release formulations.
    Bechgaard H; Brodie RR; Chasseaud LF; Houmøller P; Hunter JO; Siklos P; Taylor T
    Eur J Clin Pharmacol; 1982; 21(6):511-5. PubMed ID: 7075656
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic overview of indomethacin and sustained-release indomethacin.
    Yeh KC
    Am J Med; 1985 Oct; 79(4C):3-12. PubMed ID: 3904441
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of indomethacin.
    Alván G; Orme M; Bertilsson L; Ekstrand R; Palmér L
    Clin Pharmacol Ther; 1975 Sep; 18(3):364-73. PubMed ID: 1100305
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bioavailability of indomethacin from a modified release system containing indomethacin as the lysine salt.
    Marzo A; Reiner A; Arrigoni Martelli E; Conte U; Colombo P; La Manna A
    Eur J Clin Pharmacol; 1987; 32(1):85-7. PubMed ID: 3108010
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect in man of aspirin, standard indomethacin, and sustained release indomethacin preparations on gastric bleeding.
    Prichard PJ; Poniatowska TJ; Willars JE; Ravenscroft AT; Hawkey CJ
    Br J Clin Pharmacol; 1988 Aug; 26(2):167-72. PubMed ID: 3264710
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chronopharmacokinetic study of a prolonged release form of indomethacin.
    Guissou P; Cuisinaud G; Llorca G; Lejeune E; Sassard J
    Eur J Clin Pharmacol; 1983; 24(5):667-70. PubMed ID: 6873148
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of new indomethacin dosage forms.
    Waller ES
    Pharmacotherapy; 1983; 3(6):324-33. PubMed ID: 6361702
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics and safety of low-dose submicron indomethacin 20 and 40 mg compared with indomethacin 50 mg.
    Olugemo K; Solorio D; Sheridan C; Young CL
    Postgrad Med; 2015 Mar; 127(2):223-31. PubMed ID: 25639879
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A clinical and pharmacokinetic study of indomethacin in standard and slow release formulations.
    Adams KR; Halliday LD; Sibeon RG; Baber N; Littler T; Orme ML
    Br J Clin Pharmacol; 1982 Aug; 14(2):286-9. PubMed ID: 7104182
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The influence of food and repeated dosing on the bioavailability of indomethacin from a multiple-units controlled-release formulation.
    Skinhøj A; Bechgaard H; Chasseaud LF; Brodie RR; Sharman JM; Taylor T; Hunter JO
    Int J Clin Pharmacol Ther Toxicol; 1984 Oct; 22(10):557-61. PubMed ID: 6511132
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bioavailability of indomethacin tablets in men volunteers.
    Groth PE; Dunn JM
    Clin Pharm; 1986 Oct; 5(10):820-4. PubMed ID: 3780150
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of sustained release on the pharmacokinetic profile of indomethacin in man.
    Yeh KC; Berger ET; Breault GO; Lei BW; McMahon FG
    Biopharm Drug Dispos; 1982; 3(3):219-30. PubMed ID: 7139063
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics and tolerance of slow-release indomethacin tablets in rheumatoid arthritis.
    Kaarela K; Lehtinen K; Mäkisara P; Holttinen K; Lamminsivu U; Gordin A
    Eur J Clin Pharmacol; 1982 Oct; 23(4):349-51. PubMed ID: 7173304
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.